Reverso Therapeutics Secures CHF 710,000 Innosuisse Grant

Reverso Therapeutics, a University of Geneva (UNIGE) pharmaceutical spin-off, and winner of the Bioinnovation Day Best Academic Project Award 2025, has been awarded a CHF 710,000 grant from Innosuisse to accelerate the development of its breakthrough reversible anticoagulant technology.

Today, millions of patients worldwide rely on anticoagulants to prevent life-threatening blood clots. Yet existing therapies carry major risks: bleeding events can escalate rapidly, and many commonly prescribed drugs lack a fast, safe, and affordable way to stop their action. Some can even trigger paradoxical clotting in certain cases.

Reverso Therapeutics is addressing these challenges with a revolutionary supramolecular anticoagulant inspired by natural biological mechanisms. Developed using a novel peptide-nucleic-acid–based design, the therapy is both highly potent and instantly reversible. Its action can be stopped on demand with a simple antidote—potentially even outside of a hospital setting—transforming the management of bleeding complications.

This innovation has already demonstrated strong preclinical results and was independently peer-reviewed and published in Nature Biotechnology. The study showed that the drug can effectively prevent thrombosis in vivo and that its activity can be rapidly neutralised by administering the antidote.

This funding will support synthetic feasibility work and extensive in vivo efficacy and benchmarking studies, bringing the company’s lead compound closer to pre-clinical development.

➡️ Source: Reverso Therapeutics | 📸 © Reverso Therapeutics. Phd Millicent Dockerill and Prof. Nicolas Wissinger